A number of other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a buy rating and issued a $6.00 price objective on shares of Selecta Biosciences in a research note on Tuesday, January 11th. Zacks Investment Research raised shares of Selecta Biosciences from a strong sell rating to a hold rating in a research note on Tuesday, January 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of Buy and an average price target of $6.25.
NASDAQ:SELB opened at $1.09 on Friday. The company has a fifty day moving average price of $1.71. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.00 and a current ratio of 2.00. Selecta Biosciences has a 52 week low of $1.07 and a 52 week high of $5.28. The company has a market cap of $135.48 million, a price-to-earnings ratio of -3.11 and a beta of 1.17.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. raised its holdings in Selecta Biosciences by 9.5% during the second quarter. Invesco Ltd. now owns 29,138 shares of the company’s stock worth $122,000 after buying an additional 2,522 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Selecta Biosciences by 138.2% during the second quarter. Wells Fargo & Company MN now owns 54,827 shares of the company’s stock worth $229,000 after buying an additional 31,805 shares during the last quarter. Strs Ohio raised its holdings in Selecta Biosciences by 335.6% during the third quarter. Strs Ohio now owns 37,900 shares of the company’s stock worth $157,000 after buying an additional 29,200 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in Selecta Biosciences by 72.9% during the third quarter. Los Angeles Capital Management LLC now owns 18,637 shares of the company’s stock worth $78,000 after buying an additional 7,860 shares during the last quarter. Finally, WNY Asset Management LLC acquired a new position in Selecta Biosciences during the third quarter worth $49,000. 73.16% of the stock is currently owned by institutional investors and hedge funds.
Selecta Biosciences Company Profile (Get Rating)
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.
- Get a free copy of the StockNews.com research report on Selecta Biosciences (SELB)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.